Great businesses at fair prices — here's why each makes the list.
…and 348 more buy candidates in the full briefing.
41 name(s) sliding toward Avoid:
Value $108,062 ▲ +8.1% since 2026-07-16 · ▼ -$918 (-0.8%) since yesterday · S&P +1.7% · Cash $3,897
| Stock | Held | Price | Today | Since buy | Grade |
| CF | 83 sh | $127.26 | ▼ -1.5% | -1.8% | 89 |
| EOG | 78 sh | $146.83 | ▼ -2.3% | +9.0% | 88 |
| FHI | 156 sh | $65.39 | ▲ +1.0% | +9.1% | 92 |
| HIG | 73 sh | $138.22 | ▼ -0.5% | +1.1% | 90 |
| INTU | 33 sh | $357.46 | ▼ -3.4% | +21.3% | 87 |
| LOPE | 69 sh | $149.08 | ▲ +1.0% | +4.1% | 90 |
| LULU | 85 sh | $118.33 | ▼ -3.6% | -0.5% | 88 |
| NBIX | 58 sh | $153.37 | ▲ +0.2% | -10.6% | 89 |
| PRI | 31 sh | $297.72 | ▼ -0.8% | -4.8% | 93 |
| RMD | 49 sh | $236.59 | ▲ +1.8% | +16.7% | 84 |
Fictional money · prices update daily · a live test of whether the picks actually work.
Does the grading actually work? Two honest halves — a backtest on past data, and the real live record as it ripens. It reports the truth even when that's “not enough data yet.”
Reconstructed 319 graded moments across 150 companies (a sample of 150 names), then measured what each actually returned over the next 12 months.
Do higher grades earn better returns?
| Grade | Names | 12-mo return | vs S&P |
| A (80-100) | 43 | +13.5% | -0.5% |
| B (65-79) | 161 | +11.9% | -3.6% |
| C (50-64) | 91 | +12.9% | -1.7% |
| D-F (<50) | 24 | +41.0% | +27.2% |
→ higher grades did WORSE here (gap 27.5 pts) ⚠️
27 snapshot(s) since 2026-07-06, none ripe yet — first 6-month check ~2027-01-06.
Backtest limits: ~5 years back, surviving companies only, restated statements — a strong first read, not gospel. The live record is the hindsight-free gold standard and strengthens every month. Refreshed 2026-08-23. Educational only — not financial advice.
News is context alongside the grade, not a substitute for it. If news and grade
disagree, both are shown honestly and the call is yours.
UBS warns full-year guidance cut is coming. Ahead of the Sep 3 earnings call, UBS
expects Lululemon to slash its fiscal 2026 EPS guidance by ~$1.25 (to $9.70-$9.90),
well below Wall Street's $10.93 consensus. The culprits: weak demand in both the US
and China. UBS sees Q2 earnings slightly beating ($1.84 vs $1.82 consensus) thanks to
cost control and buybacks, but the full-year outlook is the real story. They kept a
Neutral rating and trimmed their price target to $120.
Meanwhile, Michael Burry nearly doubled his LULU position — it's now 17.4% of his
portfolio. He calls the stock "screaming cheap," pointing to tangible book value
doubling from ~$20 to ~$40/share in three years. Burry sees the market pricing in too
much pessimism, similar to his early GameStop thesis.
On the management front, Lululemon promoted its China head to lead all of Asia-Pacific
and hired a former Louis Vuitton executive for a regional role — a sign of continued
international investment despite the soft demand picture.
Grade vs news: The grade (88.2) reflects LULU's strong underlying profitability and
balance sheet. The UBS warning is about near-term guidance, not the business
fundamentals the grade measures. The Sep 3 report will be worth watching closely — if
the guidance cut is as steep as UBS expects, the stock could dip further, but Burry's
position suggests the long-term value case is intact. Worth keeping on the radar; the
earnings call will be the real test.
Strong Q2 beat and raised guidance. Revenue hit $959M (up 39% YoY), well above the
$901.5M consensus. Adjusted EPS of $2.85 crushed the $2.26 estimate (+73% YoY).
Ingrezza, their lead drug for tardive dyskinesia, grew 15% in Q2 and management raised
full-year Ingrezza guidance to $2.825-$2.875B (up from $2.7-$2.8B). New drug Vykat XR
added $54M from just six weeks of sales. The beat was broad-based — this is real
operational momentum, not a one-time bump.
Grade vs news: Fully aligned. The grade's top pillar is growth (98.6), and the Q2
results confirm that the growth engine is firing. No concerns here.
Stock up 14.8% in 3 months on monster Q2 results. Adjusted EPS surged 118.5% to
$5.07 (beat by 1.2%), revenue jumped 57.4% to $8.62B (beat by 9.6%). Free cash flow
reached $2.8B, up from $973M a year ago. Production rose 24.4% with composite realized
prices up 51.4%. The company is targeting returning 70% of FCF to shareholders.
The CEO did sell $5.47M in stock — at this price level, this looks like planned
profit-taking rather than a red flag, consistent with a stock that's rallied hard.
Caution: 2027 earnings are expected to decline ($14.12 vs $16.87 in 2026), so the
rally has less room for error. Commodity-price risk is always present in energy names.
Shares fell ~3.8% in a broad footwear/apparel selloff triggered by weak Dick's
Sporting Goods earnings. The concern: excess inventory in athletic shoes is driving a
promotional environment, and softening retail demand threatens wholesale profitability
across the sector. This hit DECK alongside VF Corp, Levi's, Under Armour, and Crocs.
Grade vs news: The selloff is sector-wide contagion, not DECK-specific. Deckers'
HOKA and UGG brands have been gaining international traction. The grade still reflects
strong fundamentals — but keep an eye on whether the promotional environment starts
eating into DECK's margins at next earnings.
President sold 1,800 shares ($562,770). Peter Schneider trimmed his stake by 18%
at ~$312.65/share. PRI stock is up 16.1% in 2026 (vs S&P's 11.7%), and Q2 showed
revenue +9%, net income +13%. This looks like routine profit-taking after a strong run,
not a warning signal. Analyst targets suggest another ~12.5% upside (median $337.50).
No material business news. Quiet is good for a steady compounder.
Upgraded to Zacks #1 (Strong Buy). Driven by a 7.8% upward revision in consensus
earnings estimates over the past three months. That puts FHI in the top 5% of
Zacks-covered stocks for estimate revisions. An exec (EVP/CLO Peter Germain) also sold
some shares — at these levels, routine.
No dramatic catalyst, but steadily improving analyst expectations is a healthy sign for
a name already scoring 91.5.
Partnered with UC Berkeley's Bakar Labs to support startups in energy and materials
tech. The Hartford will provide insurance and risk-management expertise to early-stage
companies. It's a modest, forward-looking initiative (the incubator doesn't open until
2028) — not an immediate revenue driver, but positions them in emerging tech
underwriting.
Brokerages average a "Hold" rating — the grade at 90.3 is more bullish than the
Street's consensus, mainly because the valuation pillar (P/E 10, FCF yield 14.7%)
scores a perfect 100. The numbers back a very cheap stock.
Shares gapped down — the headline flagged a price drop, but no specific negative
catalyst was identified in the articles. An SEC 8-K was filed on Aug 21 but the filing
itself was not accessible (SEC returned 403). Institutional buying continues (Algert
Global, Quantbot). Analysts maintain a "Moderate Buy" consensus.
Without being able to read the 8-K, this gap-down could be noise or could be material.
The grade remains strong at 89.6 with virtually no debt and a perfect stability score
(97.0). Worth monitoring but nothing confirmed yet.
No company-specific catalyst. The news is mostly sector-level: energy/commodity
trade discussions and daily stock-performance blurbs. CF continues to screen well on
fundamentals, but this was a quiet week for the name.
Highlighted as a "watchlist" financial stock with 10.8% annual revenue growth
(above sector average), effective capital allocation via buybacks, and strong return on
equity. At 13x forward P/E, it's reasonably valued. An SEC 8-K was filed Aug 19 but the
SEC page returned 403, so I couldn't read the filing. A COO gifted 1,000 shares — a
gift, not a sale.
The firm itself made headlines by upgrading AMD to Strong Buy, which shows the research
side of the business is active and visible — good for brand but not directly
needle-moving for RJF's stock.
Wells Fargo initiated coverage at Equal Weight, $42 target. They see potential in
self-help initiatives long-term but cite a "tough discretionary environment" and
"persistent promotions" as near-term headwinds. Separately, an analyst piece flagged
revenue declining 7.3% annually over five years, EPS falling 38.4% annually, and a
concerning 9x net-debt-to-EBITDA ratio.
Grade vs news: Fully aligned. The grade of 45.4 reflects exactly these problems —
weak finances, shrinking revenue, and heavy debt. No reason to reconsider.
Took on $350M in new debt; Blackstone deal not a change of control. An SEC 8-K was
filed Aug 19 (couldn't access the full filing). The headline confirms more leverage
being added, and Balyasny Asset Management trimmed its stake. For a utility already on
crash watch, adding debt is the opposite of what you want to see.
Interesting pivot to powering AI data centers with geothermal energy. Revenue was
up 43% YoY in H1 2026 ($662.7M), and the company is partnering with Google and Switch
to build large-scale geothermal plants using enhanced geothermal systems (EGS). The CEO
sees "endless demand" from hyperscalers. Pilot projects could be running by late 2027.
Grade vs news: This is a case where the news is more optimistic than the grade.
ORA's low score (45.4) likely reflects valuation and financial health concerns — the
stock may be priced for a lot of this AI-geothermal future already. An intriguing story,
but the grade says the current price is rich relative to current fundamentals. Both
views are honest; the question is whether the pivot delivers on its promise.
No material company-specific news. All headlines were institutional buy/sell
filings (MarketBeat-style fund disclosure stories). Nothing actionable.
No material company-specific news. The only substantive piece was a Seeking Alpha
article calling NNN "an undervalued dividend champion with a 5.4% yield" — contrarian
to the grade's assessment. REIT analysts tend to focus on yield and dividend growth,
while the grade weighs growth and valuation more broadly. The disagreement is a feature,
not a bug: NNN may work for income investors even if it doesn't score well on the
growth-oriented grading system.
- SEC 8-K filings for LOPE and RJF returned HTTP 403 (access denied). These could
contain material events that I couldn't verify.
- Retail Dive article on Lululemon's communications chief exit loaded only as
JavaScript — no readable content.
- TheStreet article on the "next big oil trade" (relevant to CF Industries) returned
HTTP 403.
- Google News redirect links (MarketBeat, GuruFocus, etc.) were not fetched — these
are almost all institutional fund-filing roundups, not material news.
MarketMind is a personal, educational stock-research tool. Every morning it screens roughly 900 large- and mid-cap U.S. companies, grades each one from 0–100 on five research-backed pillars — financial health, profitability, growth, valuation, and moat — and surfaces the businesses that look strong and reasonably priced.
The idea it rests on: over the long run, a stock's price follows the company's profits. So rather than chasing hype, MarketMind looks for great businesses at fair prices and lets time do the work.
It also runs a Paper Fund — a fictional $100,000 that automatically follows the tool's own Buy ratings — so you can watch, over time, whether the picks actually work. It's pretend money: nothing here is ever bought or sold for real.
Built with free public data · refreshed every morning at 7:00 AM U.S. Central time.